Leon Herndon Jr, MD, a glaucoma specialist, ophthalmologist, and professor of ophthalmology at the Duke University Eye Center, discusses how a patient’s age can affect their glaucoma symptoms and treatment.
As patients live longer, ophthalmologists need to revisit the notion that older patients may not need as aggressive treatment for glaucoma as younger patients, said Leon Herndon Jr, MD, a glaucoma specialist, ophthalmologist, and professor of ophthalmology at the Duke University Eye Center.
Transcript
Can you introduce yourself and explain your work?
My name is Leon Herndon, professor of ophthalmology at the Duke University Eye Center, where I'm the chief of the glaucoma division. My passion really deals with taking care of glaucoma patients and teaching the next generation of glaucoma specialists.
How can a patient's age impact the diagnosis and treatment of primary open-angle glaucoma?
Well, we know that the incidence of glaucoma increases as patients get older, and the population is getting older. We know that if you look at life table analysis, a 90-year-old patient has another 4 to 5 years to live. It really would be nice to know how long each patient will live, but we just don't have that ability to predict that. But from a lot of work out of the Duke Glaucoma Registry, we know that older patients tend to lose nerve fiber layer at a greater rate than younger patients. So, the classic teaching has been that the older the patient is, that we're not quite as aggressive with management of their glaucoma as we might be with a younger patient, who has many more years to live. But we need to revisit that. These older patients will live longer, and they may continue to lose vision if we don't pay attention to their intraocular pressures.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More